{"pageProps":{"initialStudiesData":{"page":{"totalFilteredElements":384},"studies":[{"active":true,"description":"Prospective Registry Study: Metastatic Soft Tissue Sarcoma<div>DRKS00035722<br /><div><br /></div></div>","eudractNumber":null,"id":11205,"indications":[{"id":"sar","name":"Sarkome"},{"id":"sar1","name":"Knochensarkome (Ewing-Sarkom, Osteosarkom etc.)"},{"id":"sar2","name":"Weichteilsarkome (Liposarkom, Leiomyosarkom, etc.)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2025-08-17T09:43:09+02:00","shortTitle":"STS-met","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<p class=\"MsoNormal\">A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)</p><p class=\"MsoNormal\"><b>CA057-001</b></p>","eudractNumber":"2023-509859-13","id":10285,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05519085","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-03-13T15:17:15+01:00","shortTitle":"SUCCESSOR-1","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"SURVIVE (Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer) - a partially double-blinded, multicenter, randomized, controlled superiority study<div><br /></div><div>DRKS00030745<br /></div>","eudractNumber":null,"id":9451,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05658172","phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-03-25T14:00:01+01:00","shortTitle":"SURVIVE","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Screening Programm auf hypermutierte Tumore mit potentiell h&#246;herer Immunogenit&#228;t und Response auf Immun-Checkpoint-Inhibitoren (PD-1 Blockade)","eudractNumber":null,"id":3702,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"MSI (Mikrosatelitteninstabilität)","id":"mt_51"}],"nctNumber":null,"phase":null,"recruitmentStart":"2017-05-03T09:47:23+02:00","shortTitle":"Screen-Hyper","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prospective, international, multicenter non AMG/MPG study do detect possible markers for prediction of seroma develpment and risk assessment of a breast seroma after mastectomy with or without implant-based breast reconstruction","eudractNumber":null,"id":11681,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05899387","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2025-03-10T13:38:44+01:00","shortTitle":"SerMa - Seroma of the Mammary gland","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Register f&#252;r Weichteilsarkome (engl. Soft tissue Sarcoma; STS) und andere Weichteiltumore bei Kindern, Jugendlichen und jungen Erwachsenen.","eudractNumber":null,"id":12045,"indications":[{"id":"sar","name":"Sarkome"},{"id":"sar1","name":"Knochensarkome (Ewing-Sarkom, Osteosarkom etc.)"},{"id":"sar2","name":"Weichteilsarkome (Liposarkom, Leiomyosarkom, etc.)"},{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2026-06-12T09:36:56+02:00","shortTitle":"SoTiSaR 2.0-NIS","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"<div>Etablierung einer objektiven digitalen Sprachqualit&#228;tstestung f&#252;r Patienten</div><div>nach Stimmrehabilitation nach totaler Kehlkopfentfernung</div>","eudractNumber":null,"id":9722,"indications":[{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2022-06-01T08:43:32+02:00","shortTitle":"Sprachverständlichkeit nach Laryngektomie","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Studien-, Dokumentations- und Qualit&#228;tszentrum der Deutschen Gesellschaft f&#252;r Allgemein- und Viszeralchirurgie","eudractNumber":null,"id":7997,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"sch","name":"Schilddrüsenkarzinom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2012-01-01T09:16:52+01:00","shortTitle":"StuDoQ_Kolon_Pankreas_Schilddrüse","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<p class=\"MsoNormal\">Strukturelle und molekulare Grundlage von Schmerz und\nSchmerzr&#252;ckbildung bei genetisch bedingten Neuropathien</p>","eudractNumber":null,"id":5982,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2021-07-01T14:05:59+02:00","shortTitle":"Studienprojekt zu Erkrankungen der periphere Nerven","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Krebs als existentielle Bedrohung:<br />Die Rolle von Suizidgedanken, Demoralisierung, Kontrollverlust und assoziierten Faktoren<div><br /></div><div><br /></div>","eudractNumber":null,"id":10541,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2024-08-26T09:06:42+02:00","shortTitle":"Suizidgedanken in der Onkologie","therapeutical":false,"therapyLines":[]}]},"initialUrl":"/api/studies?lang=de&page=35&size=10","jsonDlt":"{\"name\":\"Studien des CCC Mainfranken\",\"numberOfItems\":10,\"itemListElement\":[{\"position\":1,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Prospective Registry Study: Metastatic Soft Tissue Sarcoma<div>DRKS00035722<br /><div><br /></div></div>\",\"name\":\"STS-met\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11205\"}},{\"position\":2,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"<p class=\\\"MsoNormal\\\">A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)</p><p class=\\\"MsoNormal\\\"><b>CA057-001</b></p>\",\"name\":\"SUCCESSOR-1\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/10285\"}},{\"position\":3,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"SURVIVE (Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer) - a partially double-blinded, multicenter, randomized, controlled superiority study<div><br /></div><div>DRKS00030745<br /></div>\",\"name\":\"SURVIVE\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/9451\"}},{\"position\":4,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Screening Programm auf hypermutierte Tumore mit potentiell h&#246;herer Immunogenit&#228;t und Response auf Immun-Checkpoint-Inhibitoren (PD-1 Blockade)\",\"name\":\"Screen-Hyper\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/3702\"}},{\"position\":5,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Prospective, international, multicenter non AMG/MPG study do detect possible markers for prediction of seroma develpment and risk assessment of a breast seroma after mastectomy with or without implant-based breast reconstruction\",\"name\":\"SerMa - Seroma of the Mammary gland\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11681\"}},{\"position\":6,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Register f&#252;r Weichteilsarkome (engl. Soft tissue Sarcoma; STS) und andere Weichteiltumore bei Kindern, Jugendlichen und jungen Erwachsenen.\",\"name\":\"SoTiSaR 2.0-NIS\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/12045\"}},{\"position\":7,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"<div>Etablierung einer objektiven digitalen Sprachqualit&#228;tstestung f&#252;r Patienten</div><div>nach Stimmrehabilitation nach totaler Kehlkopfentfernung</div>\",\"name\":\"Sprachverständlichkeit nach Laryngektomie\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/9722\"}},{\"position\":8,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Studien-, Dokumentations- und Qualit&#228;tszentrum der Deutschen Gesellschaft f&#252;r Allgemein- und Viszeralchirurgie\",\"name\":\"StuDoQ_Kolon_Pankreas_Schilddrüse\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/7997\"}},{\"position\":9,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"<p class=\\\"MsoNormal\\\">Strukturelle und molekulare Grundlage von Schmerz und\\nSchmerzr&#252;ckbildung bei genetisch bedingten Neuropathien</p>\",\"name\":\"Studienprojekt zu Erkrankungen der periphere Nerven\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/5982\"}},{\"position\":10,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Krebs als existentielle Bedrohung:<br />Die Rolle von Suizidgedanken, Demoralisierung, Kontrollverlust und assoziierten Faktoren<div><br /></div><div><br /></div>\",\"name\":\"Suizidgedanken in der Onkologie\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/10541\"}}],\"url\":\"https://cccmf-studien-homepage.vercel.app/studies?page=36\"}","__lang":"de","__namespaces":{"common":{"app_title":"Comprehensive Cancer Center Mainfranken Studiendatenbank","app_description":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","app_version":"Version","central_contacts":"Ihre Ansprechpartnerin im CCC MF","email_label":"E-Mail","contact_info_email":"anmeldung_ccc@ukw.de","contact_info_email_title":"E-Mail der Anmeldung des Comprehensive Cancer Center Mainfranken","fax_label":"Fax","contact_info_fax_number":"+49 931 201-35359","contact_info_fax_number_title":"Faxnummer des Comprehensive Cancer Center Mainfranken","phone_label":"Tel.","contact_info_phone_number":"+49 931 201-35350","contact_info_phone_number_title":"Telefonnummer des Comprehensive Cancer Center Mainfranken","website_label":"Webseite","contact_info_website":"https://www.med.uni-wuerzburg.de/ccc/startseite/","contact_info_website_title":"Webseite des Comprehensive Cancer Center Mainfranken","comprehensive_cancer_center_mainfranken_cccmf":"Comprehensice Cancer Centers Mainfranken (CCC MF)","profile_picture_alt_text":"Foto von {{ name }}","close_menu_title":"Studienfilter ausblenden","open_menu_title":"Studienfilter einblenden","search_button_label":"Suchen","text_field_search_label":"Suche...","text_field_clear_buton_title":"Textfeld leeren","hide_filter_button_text":"Filter ausblenden","show_filter_button_text":"Filtern","back_url_title":"Zurück","imprint":"Impressum","data_protection":"Datenschutz","accessibility":"Barrierefreiheit","studies_list_breadcrumb_label":"Studienliste","tree_view_check_boxes_number_of_studies":"{{numberOfStudies}} Treffer, wenn dieser Filter aktiviert wird","footer_logo_ccc_title":"Zur Webseite des CCC Mainfranken","footer_logo_ozw_title":"Zur Webseite des Onkologischen Zentrums Würzburg","footer_logo_ukw_title":"Zur Webseite des Universitätsklinikums Würzburg","footer_logo_isz_ectu_title":"Zur Webseite des Interdisziplinären Studienzentrums mit ECTU","loading":"Laden...","landing_page_name":"Startseite","theme_dark":"Hell","theme_light":"Dunkel","study_status_active":"Rekrutierung läuft","study_status_inactive":"Rekrutierung beendet"},"filters":{"includeinactive":"Nicht rekrutierende Studien auch anzeigen","indications":"Nach Erkrankungen filtern","isonly":"Nur Therapiestudien anzeigen","therapy_lines":"Nach Therapielinien filtern","mutations":"Nach molekularen Markern filtern","organizations":"Nach studienaktiven Standorten filtern","phases":"Nach Phasen filtern","reset_filter":"Filter zurücksetzen","filters_selected_alert_message":"Filter aktiv","reset_all_filters":"Filter zurücksetzen","close_filters_menu":"Zurück zu den Suchergebnissen"},"home":{"banner_alt":"Logo des Comprehensive Cancer Center Mainfranken","logo_alt":"Logo des Comprehensive Cancer Center Mainfranken","subtitle":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","title":"CCC MF Studiendatenbank"},"paginatedList":{"number_of_items_found_text":"Seite {{page}} - Studien {{start}} bis {{end}} von insgesamt {{total}}","no_items_found":"Es wurden keine Einträge gefunden.","pagination_item_aria_label_current_page":"Aktuelle Seite, Seite {{page}}","pagination_item_aria_label_page":"Zu Seite {{page}} navigieren","pagination_item_aria_label_next_page":"Zur nächsten Seite, Seite {{page}} navigieren","pagination_item_aria_label_previous_page":"Zur vorherigen Seite, Seite {{page}} navigieren"},"studiesList":{"alert_text":"Hier finden Sie grundlegende Angaben zu klinischen Studien des ","button_aria_label_details":"Zu den Details der Studie {{shortTitle}}","button_label_details":"Mehr Informationen","indications":"Indikationen","mutations":"Molekulare Marker"}}},"__N_SSP":true}